Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Xu, Hui  [Clear All Filters]
2018
Wang L-Q, Yu P, Li B, Guo Y-H, Liang Z-R, Zheng L-L, Yang J-H, Xu H, Liu S, Zheng L-S, et al. miR-372 and miR-373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways. Mol Oncol. 2018.
2019
Jiang N, Guo F, Sun B, Zhang X, Xu H. Different Effects of Fluoride Exposure on the Three Major Bone Cell Types. Biol Trace Elem Res. 2019.
Li J, Zhang L, Yin L, Ma N, Wang T, Wu Y, Wang M, Yang X, Xu H, Hao C, et al. In vitro Expansion of Hematopoietic Stem Cells by Inhibition of Both GSK3 and p38 Signaling. Stem Cells Dev. 2019.
Liu L-P, Li Y-M, Guo N-N, Li S, Ma X, Zhang Y-X, Gao Y, Huang J-L, Zheng D-X, Wang L-Y, et al. Therapeutic Potential of Patient iPSC-Derived iMelanocytes in Autologous Transplantation. Cell Rep. 2019;27(2):455-466.e5.
2020
Guo M, Luo B, Pan M, Li M, Xu H, Zhao F, Dou J. Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer. Int Immunopharmacol. 2020;88:106850.
Zhang L, Li J, Xu H, Shao X, Fu L, Hou Y, Hao C, Li W, Joshi K, Wei W, et al. Myc-Miz-1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ. Blood. 2020.
2021
Li Y, Li Y, Yin J, Wang C, Yang M, Gu J, He M, Xu H, Fu W, Zhang W, et al. A mitophagy inhibitor targeting p62 attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Lett. 2021.
2022
Tan X, Wang D, Lu P, Guan S, Zheng Q, Du X, Xu H. Bone marrow mesenchymal stem cells alleviate stress-induced hyperalgesia via restoring gut microbiota and inhibiting neuroinflammation in the spinal cord by targeting the AMPK/NF-κB signaling pathway. Life Sci. 2022:121318.
2023
Xu H, Zhao F, Wu D, Zhang Y, Bao X, Shi F, Cai Y, Dou J. Eliciting effective tumor immunity against ovarian cancer by cancer stem cell vaccination. Biomed Pharmacother. 2023;161:114547.
Li Y, He M, Zhang W, Liu W, Xu H, Yang M, Zhang H, Liang H, Li W, Wu Z, et al. Expansion of human megakaryocyte-biased hematopoietic stem cells by biomimetic Microniche. Nat Commun. 2023;14(1):2207.
Kolliopoulos V, Polanek M, Xu H, Harley B. Inflammatory Licensed hMSCs Exhibit Enhanced Immunomodulatory Capacity in a Biomaterial Mediated Manner. ACS Biomater Sci Eng. 2023.
Xu Q, Shi Y, Xue L, An F, Xu H, Liu X, Zhu X, Sun Z, Zhai Z, Wang X. Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy. Cell Transplant. 2023;32:9636897231204724.
Tan H-J, Jian W-Y, Lv C, Guo D-W, Liao Z-C, Xu H, Xiao Y, Schiller M, Zhuo J-L, Yue S-J, et al. Prenatal diagnosis and treatment for fetal angiotensin converting enzyme deficiency. Prenat Diagn. 2023.
Zheng YYuan, Xu H, Wang YSi. Progress in direct reprogramming of dopaminergic cell replacement therapy. Neurol Sci. 2023.
Yang J, Yan Y, Xia Y, Kang T, Li X, Ciric B, Xu H, Rostami A, Zhang G-X. Retraction Notice to: Neurotrophin 3 Transduction Augments Remyelinating and Immunomodulatory Capacity of Neural Stem Cells. Mol Ther. 2023;31(8):2552.
Liu C-Y, Al-Ward H, Liu N, Mekontso FNgaffo, Chen W, Gao W, Zhang C, Murshed A, Yu Z-R, Fan O, et al. The Role of Cystathionine-β-Synthase, HS, and miRNA-377 in Hypoxic-Ischemic Encephalopathy: Insights from Human and Animal Studies. J Mol Neurosci. 2023.
Li S, Guo Q, Guo R, Xu H. Transcriptional factor BRD4 promotes the stemness of esophageal cancer by activating the nuclear PD-L1/RelB axis. Environ Toxicol. 2023.
2024
Chen G, Shang J, Feng X, Li M, Zhang H, Liu J, Xu H. Facilitates Oncogenesis in Gastric Cancer Cells by Modulating miR-149 Expression. Anticancer Res. 2024;44(4):1475-1485.
Liu T, Li X, Li H, Qin J, Xu H, Wen J, He Y, Zhang C. Intestinal organoid modeling: bridging the gap from experimental model to clinical translation. Front Oncol. 2024;14:1334631.